Humanexa — Pharma Intelligence OS

Showing signals for 2026-06-02

Decision-support intelligence — prioritized by importance, with recommended actions for each signal.

Comparative Study of SPSIPB vs Thoracic Paravertebral Block for Opioid Reduction

Positive results could lead to a shift in clinical guidelines favoring SPSIPB, affecting market dynamics for anesthetic techniques and opioid alternatives.

MonitorTrial UpdatePain ManagementAnesthesiaTrial Update

Pilot Study on Geniculate Artery Embolization for Knee Osteoarthritis Initiated

If successful, this could lead to a shift in treatment paradigms for knee OA, influencing portfolio strategies for companies involved in OA therapies.

MonitorTrial UpdateMusculoskeletalOsteoarthritisTrial Update

Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial

Portfolio teams should consider the implications of this combination therapy for future treatment guidelines and market access strategies.

InvestigateTrial UpdateOncologyLiver CancerTrial Update

Efzimfotase alfa shows positive Phase III results in hypophosphatasia

The success of efzimfotase alfa may prompt strategic shifts in marketing and development for competing therapies in the rare disease space.

InvestigateTrial UpdateRare DiseasesHypophosphatasiaTrial Update

Trial on Pulmonary Artery Catheters in Cardiac Surgery Aims to Compare Recovery Outcomes

If successful, this trial could lead to changes in surgical protocols, affecting device manufacturers and healthcare providers focused on cardiac surgery.

MonitorTrial UpdateCardiologySurgical InterventionTrial Update

TAPUR Study Evaluates Targeted Therapies in Advanced Cancer with Genomic Variants

Portfolio teams should monitor the outcomes of this study to identify potential shifts in treatment paradigms and opportunities for new indications.

MonitorTrial UpdateOncologyTargeted TherapyTrial Update

Tozorakimab achieves primary endpoints in Phase III trials for COPD

Strategic focus on further development and potential market entry strategies for tozorakimab in COPD, considering its novel mechanism.

InvestigateTrial UpdateRespiratoryCOPDTrial Update

Enhertu recommended for EU approval in HER2+ metastatic solid tumours

This approval could enhance AstraZeneca and Daiichi Sankyo's market position in oncology, particularly in the HER2-targeted therapy space.

InvestigateRegulatory ApprovalOncologyHER2-positive solid tumoursRegulatory Approval